scholarly journals Thermodynamic Stability Is a Strong Predictor for the Delivery of DARPins to the Cytosol via Anthrax Toxin

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1285
Author(s):  
Lukas Becker ◽  
Jasleen Singh Badwal ◽  
Fabian Brandl ◽  
Wouter P. R. Verdurmen ◽  
Andreas Plückthun

Anthrax toxin has evolved to translocate its toxic cargo proteins to the cytosol of cells carrying its cognate receptor. Cargo molecules need to unfold to penetrate the narrow pore formed by its membrane-spanning subunit, protective antigen (PA). Various alternative cargo molecules have previously been tested, with some showing only limited translocation efficiency, and it may be assumed that these were too stable to be unfolded before passing through the anthrax pore. In this study, we systematically and quantitatively analyzed the correlation between the translocation of various designed ankyrin repeat proteins (DARPins) and their different sizes and thermodynamic stabilities. To measure cytosolic uptake, we used biotinylation of the cargo by cytosolic BirA, and we measured cargo equilibrium stability via denaturant-induced unfolding, monitored by circular dichroism (CD). Most of the tested DARPin cargoes, including target-binding ones, were translocated to the cytosol. Those DARPins, which remained trapped in the endosome, were confirmed by CD to show a high equilibrium stability. We could pinpoint a stability threshold up to which cargo DARPins still get translocated to the cytosol. These experiments have outlined the requirements for translocatable binding proteins, relevant stability measurements to assess translocatable candidates, and guidelines to further engineer this property if needed.

Toxins ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 53
Author(s):  
Zoe Couse ◽  
Xizhong Cui ◽  
Yan Li ◽  
Mahtab Moayeri ◽  
Stephen Leppla ◽  
...  

Anti-toxin agents for severe B. anthracis infection will only be effective if they add to the benefit of the two mainstays of septic shock management, antibiotic therapy and titrated hemodynamic support. Both of these standard therapies could negate benefits related to anti-toxin treatment. At present, three anthrax anti-toxin antibody preparations have received US Food and Drug Administration (FDA) approval: Raxibacumab, Anthrax Immune Globulin Intravenous (AIGIV) and ETI-204. Each agent is directed at the protective antigen component of lethal and edema toxin. All three agents were compared to placebo in antibiotic-treated animal models of live B. anthracis infection, and Raxibacumab and AIGIV were compared to placebo when combined with standard hemodynamic support in a 96 h canine model of anthrax toxin-associated shock. However, only AIG has actually been administered to a group of infected patients, and this experience was not controlled and offers little insight into the efficacy of the agents. To provide a broader view of the potential effectiveness of these agents, this review examines the controlled preclinical experience either in antibiotic-treated B. anthracis models or in titrated hemodynamic-supported toxin-challenged canines. The strength and weaknesses of these preclinical experiences are discussed.


1991 ◽  
Vol 266 (23) ◽  
pp. 15493-15497
Author(s):  
Y. Singh ◽  
K.R. Klimpel ◽  
C.P. Quinn ◽  
V.K. Chaudhary ◽  
S.H. Leppla

1994 ◽  
Vol 269 (46) ◽  
pp. 29039-29046
Author(s):  
Y Singh ◽  
K R Klimpel ◽  
N Arora ◽  
M Sharma ◽  
S H Leppla

Author(s):  
Alexandra Kosareva ◽  
Mukesh Punjabi ◽  
Amanda Ochoa-Espinosa ◽  
Lifen Xu ◽  
Jonas V. Schaefer ◽  
...  

2005 ◽  
Vol 8 (1) ◽  
pp. 106-112 ◽  
Author(s):  
Heather M Scobie ◽  
John AT Young

2006 ◽  
Vol 13 (6) ◽  
pp. 671-677 ◽  
Author(s):  
Robert Mabry ◽  
Kathleen Brasky ◽  
Robert Geiger ◽  
Ricardo Carrion ◽  
Gene B. Hubbard ◽  
...  

ABSTRACT Several strategies that target anthrax toxin are being developed as therapies for infection by Bacillus anthracis. Although the action of the tripartite anthrax toxin has been extensively studied in vitro, relatively little is known about the presence of toxins during an infection in vivo. We developed a series of sensitive sandwich enzyme-linked immunosorbent assays (ELISAs) for detection of both the protective antigen (PA) and lethal factor (LF) components of the anthrax exotoxin in serum. The assays utilize as capture agents an engineered high-affinity antibody to PA, a soluble form of the extracellular domain of the anthrax toxin receptor (ANTXR2/CMG2), or PA itself. Sandwich immunoassays were used to detect and quantify PA and LF in animals infected with the Ames or Vollum strains of anthrax spores. PA and LF were detected before and after signs of toxemia were observed, with increasing levels reported in the late stages of the infection. These results represent the detection of free PA and LF by ELISA in the systemic circulation of two animal models exposed to either of the two fully virulent strains of anthrax. Simple anthrax toxin detection ELISAs could prove useful in the evaluation of potential therapies and possibly as a clinical diagnostic to complement other strategies for the rapid identification of B. anthracis infection.


2002 ◽  
Vol 99 (10) ◽  
pp. 7045-7048 ◽  
Author(s):  
J. Mogridge ◽  
K. Cunningham ◽  
D. B. Lacy ◽  
M. Mourez ◽  
R. J. Collier

Sign in / Sign up

Export Citation Format

Share Document